Aberrant expression of FcγRIIIA (CD16) contributes to the development of atherosclerosis

被引:13
|
作者
Huang, Ye [1 ]
Yin, Huijun [1 ]
Wang, Jingshang [1 ]
Liu, Qian [1 ]
Wu, Caifeng [1 ]
Chen, Keji [1 ]
机构
[1] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Cardiovasc Dis, Beijing 100091, Peoples R China
关键词
CHD; Fc gamma RIIIA; Destabilization; Adhesion; Monocytes; Inflammation; MATRIX-METALLOPROTEINASES; RECEPTORS; INFLAMMATION; MONOCYTES; CULTURE; TARGETS; MOUSE; BLOOD;
D O I
10.1016/j.gene.2012.02.006
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Previous studies have documented that Fc receptor III A of immunoglobulin G (Fc gamma RIIIA, also named CD16) is involved in the development of coronary heart disease (CHD). However, the mechanism responsible for Fc gamma RIIIA's in contribution to CHD development remains largely unclear. Herein, we investigated the possible role of Fc gamma RIIIA in the development of atherosclerosis. Our results showed that the elevated level of Fc gamma RIIIA on monocytes closely correlated to the adhesive efficiency of human umbilical vein endothelial cells (HUVECs) in vitro. Importantly, we also observed increased population of CD16(+) monocytes and elevated CD16 level on monocytes in ApoE(-/-) mice with characterized atherosclerosis after feeding with high-fat diet for 10 weeks. The enhancement of CD16 on monocytes closely correlated to increased content of MMP-9 in aorta and increased inflammatory cytokines in sera. In addition, similar to simvastatin, recombinant human M-CSF represented a robust inhibitory influence on plaque instability and inflammation. Taken together, these data established that Fc gamma RIIIA (CD16)-mediated signaling orchestrated by interaction between monocytes and HUVECs, coupled with inflammatory cytokine stimulation and MMP activation, as a fundamental pathway linked to the development of atherosclerotic formation. Inhibition of Fc gamma RIIIA or its signaling thus might represent a promising approach for the prevention and treatment of CHD. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:91 / 95
页数:5
相关论文
共 50 条
  • [1] ABERRANT EXPRESSION OF FCΓ RIIIA CONTRIBUTES TO DEVELOPMENT OF ATHEROSCLEROSIS
    Huang Ye
    Yin Huijun
    Wang Jingshang
    Liu Qian
    Cao Yali
    Liu Sijin
    Chen Keji
    HEART, 2011, 97
  • [2] A novel mutation in the FcγRIIIA gene (CD16) results in active natural killer cells lacking CD16
    Takeuchi, T
    Nakagawa, T
    Ikemoto, T
    Sasaki, M
    Makino, S
    Shimizu, A
    Ohsawa, N
    AUTOIMMUNITY, 1999, 31 (04) : 265 - 271
  • [3] Omalizumab: an anti-IgE antibody binding to CD16 (FcγRIIIa)
    Oehrl, S.
    Maas, M.
    Doebel, T.
    Meisel, S.
    Pezer, S.
    Schaekel, K.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E26 - E26
  • [4] Genetic polymorphisms in FC γ RIIIA (CD16) expression on natural killer cells influence rituximab binding
    Hatjiharissi, E
    Santos, DD
    Hansen, M
    Tournilhac, O
    Xu, L
    Leleu, X
    Ho, A
    Branagan, A
    Hunter, Z
    Manning, R
    Anderson, K
    Verselis, S
    Fox, E
    Treon, S
    ANNALS OF ONCOLOGY, 2005, 16 : 141 - 142
  • [5] Molecular cloning and sequencing of the cDNA encoding the feline FcγRIIIA (CD16) homologue
    Nishimura, Y
    Miyazawa, T
    Ikeda, Y
    Izumiya, Y
    Nakamura, K
    Sato, E
    Mikami, T
    Takahashi, E
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2000, 73 (3-4) : 353 - 359
  • [6] Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.
    Treon, SP
    Hansen, M
    Branagan, A
    Emmanouilides, C
    Kimby, E
    Frankel, S
    Touroutoglou, N
    Maloney, D
    Anderson, KC
    Fox, EA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 571S - 571S
  • [7] The significant increase of FcγRIIIA (CD16), a sensitive marker, in patients with coronary heart disease
    Huang, Ye
    Yin, Huijun
    Wang, Jingshang
    Ma, Xiaojuan
    Zhang, Ying
    Chen, Keji
    GENE, 2012, 504 (02) : 284 - 287
  • [8] Role of FcγRIIIA (CD16) in IVIg-Mediated Anti-Inflammatory Function
    Ben Mkaddem, Sanae
    Aloulou, Meryem
    Benhamou, Marc
    Monteiro, Renato C.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S46 - S50
  • [9] Role of FcγRIIIA (CD16) in IVIg-Mediated Anti-Inflammatory Function
    Sanae Ben Mkaddem
    Meryem Aloulou
    Marc Benhamou
    Renato C. Monteiro
    Journal of Clinical Immunology, 2014, 34 : 46 - 50
  • [10] FcγRIIIa (CD16) Induction on Human T Lymphocytes and CD16pos T-Lymphocyte Amplification
    Clemenceau, Beatrice
    Vivien, Regine
    Debeaupuis, Emilie
    Esbelin, Julie
    Biron, Charlotte
    Levy, Yves
    Vie, Henri
    JOURNAL OF IMMUNOTHERAPY, 2011, 34 (07) : 542 - 549